×
About 375 results

ALLMedicine™ Acquired Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  123 results

Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell t...
https://doi.org/10.1080/16078454.2021.1959984
Hematology (Amsterdam, Netherlands); Aggarwal V, Singer Z et. al.

Aug 17th, 2021 - Methods: We report a case of a 20-year-old Nigerian male who presented with acquired thrombotic thrombocytopenic purpura (aTTP) and sickle cell trait. The coexistence of published cases of TTP and sickle cell hemoglobinopathies is rare.Results: De...

Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by I...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349569
The American Journal of Case Reports; Kubo K, Abe T et. al.

Aug 3rd, 2021 - BACKGROUND Thrombotic microangiopathy, characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage by microvascular thrombosis, has a high mortality rate; therefore, early diagnosis and treatment are important. Thromboti...

Benchmarking the centralized urgent plasma exchange service for patients admitted with ...
https://doi.org/10.1002/jca.21916
Journal of Clinical Apheresis; Seheult JN, Stram MN et. al.

Jun 26th, 2021 - Consensus guidelines recommend that therapeutic plasma exchange (TPE) should be started within 4 to 8 hours after the diagnosis of suspected acquired thrombotic thrombocytopenic purpura (aTTP). This study aimed to audit the steps from diagnosis to...

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 v...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237075
Journal of Thrombosis and Haemostasis : JTH; Maayan H, Kirgner I et. al.

Jun 10th, 2021 - In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon ha...

Clinical characteristics and outcomes of adult patients with acquired thrombotic thromb...
https://doi.org/10.21037/apm-21-759
Annals of Palliative Medicine; Huang F, Li XP et. al.

May 13th, 2021 - Thrombotic thrombocytopenic purpura (TTP) is a rare disease and a potentially life-threatening thrombotic microangiopathy. Although the diagnostic and therapeutic techniques have improved, it is still difficult for clinicians to identify early due...

see more →

Drugs  3 results see all →

News  24 results

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 16th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

A new era of TTP treatment
https://www.mdedge.com/hematology-oncology/article/196522/bleeding-disorders/new-era-ttp-treatment?channel=41022
Kristin S. Ricci, MD

Mar 18th, 2019 - Earlier this year, the Food and Drug Administration approved Cablivi (caplacizumab-yhdp) (Sanofi Genzyme, Cambridge, Mass. ) for the treatment of acquired thrombotic thrombocytopenic purpura (TTP), making it the first medication specifically indica.

FDA approves caplacizumab for aTTP
https://www.mdedge.com/clinicianreviews/article/194030/bleeding-disorders/fda-approves-caplacizumab-attp?channel=27979
Jennifer Smith

Feb 6th, 2019 - The Food and Drug Administration has approved caplacizumab (Cablivi) in combination with plasma exchange and immunosuppressive therapy for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab is an anti–vo.

Acquired TTP Drug Wins Approval
https://www.medpagetoday.com/hematologyoncology/hematology/77859

Feb 6th, 2019 - WASHINGTON -- Caplacizumab (Cablivi), an antibody drug targeting von Willebrand factor, is now approved for acquired thrombotic thrombocytopenic purpura (aTTP), the FDA said Wednesday. The drug is to be given in combination with plasma exchange an...

FDA OKs First Targeted Therapy for Rare Blood Clotting Disorder
https://www.medscape.com/viewarticle/908753

Feb 6th, 2019 - The US Food and Drug Administration (FDA) has approved caplacizumab (Cablivi, Ablynx), the first therapy specifically for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder. "Cabliv...

see more →